0, 100, 200: How Trump's latest generic medicines tariffs could affect India
US President Donald Trump has announced a phased tariff plan for imported generic medicines, starting with zero tariffs for two years followed by 100% and 200% duties. The policy aims to force pharmaceutical companies to relocate manufacturing to the United States.
Why it matters
As the largest supplier of generic drugs to the US, India's pharmaceutical industry faces significant economic risk and potential supply chain disruption.
US President Donald Trump on Wednesday unveiled a phased tariff plan for imported generic medicines, giving manufacturers a two-year window to shift production to the United States before imposing steep import duties that could significantly affect India's pharmaceutical exports.In a post on Truth Social, Trump said all generic drugs entering the US would continue to face zero tariffs from August 1, 2026, for two years, after which they would attract a 100% tariff from August 2028 and 200% from August 2029.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in